Drugs / Leukotriene B4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00251537 | Nov 2005 → Aug 2006 | HIV infectious disease | LTB4 Sweden AB | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT03192280 Background | Jun → Jul 2017 | dermatitis | LEO Pharma | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-05-12 | Yakult Honsha Co., LTD | Results アレルギー性疾患を患った犬の腸内環境の変化が明らかに ―アレルギーに関わる腸内細菌と脂質代謝の変化が見えてきた― yakult.co.jp ↗ |
| 2021-12-01 | AKARI Therapeutics | Results Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders akaritx.com ↗
Plasma levels of C5a, C5b9 and LTB4 in COVID pneumonia patients were elevated compared with control patients and increased with disease severity. |
| 2019-04-26 | AKARI Therapeutics | Results Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases akaritx.com ↗
This positive initial data from our ophthalmology program supports the potential efficacy of LTB4 and C5 inhibition in eye surface and back-of-the-eye diseases. |
| 2017-04-24 | AKARI Therapeutics | Results Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and In Additional Clinical Targets akaritx.com ↗
New preclinical data demonstrates positive response of Coversin’s combined C5 and LTB4 therapy in skin and eye models |
| 2005-05-10 | deCODE genetics | Results deCODE Paper in JAMA Describes Efficacy of DG031 in Controlling Key Indicators of Risk for Heart Attack decode.com ↗ |
| 2004-10-19 | deCODE genetics | Results deCODE Announces Positive Results from Phase IIa Clinical Trial of DG031 decode.com ↗
The results showed that at all dose levels DG031 suppressed production of leukotriene B4 (LTB4), the product of the branch of the leukotriene pathway that deCODE’s genetics research has linked to increased risk of heart attack. |
All press releases naming this drug 8 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leukotriene B4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03192280 ↗ |
| Known as | LTB4 | “Leukotriene B4 (LTB4)” NCT03192280 ↗ |
| Action | Activate | “LTB4 can activate and stimulate various white blood cells” NCT00251537 ↗ |
| Modality | Small molecule | — CHEMBL65061 ↗ |
| Route | Topical | “single topical induction application” NCT03192280 ↗ |